| Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) | Gut | 2010 | 843 |
| Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group | European Journal of Cancer | 2010 | 665 |
| First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial | Lancet, The | 2010 | 443 |
| Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate | Journal of Clinical Oncology | 2010 | 331 |
| Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer | Journal of Clinical Oncology | 2010 | 317 |
| Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study | Lancet Oncology, The | 2010 | 280 |
| A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 | Nature Genetics | 2010 | 277 |
| Envisioning the future of early anticancer drug development | Nature Reviews Cancer | 2010 | 232 |
| Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer | British Journal of Cancer | 2010 | 217 |
| High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2010 | 212 |
| Common variants at 19p13 are associated with susceptibility to ovarian cancer | Nature Genetics | 2010 | 210 |
| Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck | Clinical Cancer Research | 2010 | 189 |
| Mismatch repair deficient colorectal cancer in the era of personalized treatment | Nature Reviews Clinical Oncology | 2010 | 165 |
| All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer | Annals of Oncology | 2010 | 164 |
| Head and neck cancer--Part 1: Epidemiology, presentation, and prevention | BMJ, The | 2010 | 160 |
| Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma | Cancer Chemotherapy and Pharmacology | 2010 | 153 |
| Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force | British Journal of Cancer | 2010 | 152 |
| New strategies in estrogen receptor-positive breast cancer | Clinical Cancer Research | 2010 | 152 |
| Nipple-sparing mastectomy | British Journal of Surgery | 2010 | 145 |
| The European Society of Therapeutic Radiology and Oncology-European Institute of Radiotherapy (ESTRO-EIR) report on 3D CT-based in-room image guidance systems: a practical and technical review and guide | Radiotherapy and Oncology | 2010 | 140 |
| Influence of sex hormones on cancer progression | Journal of Clinical Oncology | 2010 | 137 |
| MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature | Cancer Research | 2010 | 130 |
| Prone versus supine positioning for whole and partial-breast radiotherapy: a comparison of non-target tissue dosimetry | Radiotherapy and Oncology | 2010 | 127 |
| Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis | British Journal of Cancer | 2010 | 109 |
| Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience | British Journal of Cancer | 2010 | 104 |
